|
Characteristics of patients (pts) with muscle-invasive urothelial carcinoma (MIUC) who received adjuvant nivolumab (NIVO) or adjuvant platinum-based chemotherapy (CHEMO) in the real-world (RW) setting. |
|
|
Honoraria - OncLive/MJH Life Sciences |
Consulting or Advisory Role - Tempus |
Research Funding - Exelixis |
|
|
Employment - Cardinal Health |
Leadership - Cardinal Health |
Stock and Other Ownership Interests - Cardinal Health |
|
|
No Relationships to Disclose |
|
|
Employment - Cardinal Health |
|
|
Employment - Cardinal Health |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Cardinal Health |
Stock and Other Ownership Interests - Cardinal Health |
Research Funding - Alexion Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb/Medarex; CVS Health (I); LEO Pharma; Pfizer (I) |
Stock and Other Ownership Interests - Bristol-Myers Squibb/Medarex; CVS Health (I); Sanofi |
|
|
Employment - Bristol Myers Squibb |
Stock and Other Ownership Interests - Bristol Myers Squibb |
Travel, Accommodations, Expenses - Bristol Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb; Merck |
Research Funding - Bristol-Myers Squibb |